The office is Hyde’s first in Europe, complementing existing sites in the US, India, China, Malaysia and Singapore. Establishing a presence in Europe is intended to improve Hyde’s ability to provide local expertise to existing clients, such as Pfizer and Lonza, and gain new business.
“With our European expansion we can now work more closely with facility manufacturers, providing new paradigms for engineering design and operations for compliance”, explained Simon Forder, CEO of Hyde.
Speaking to in-PharmaTechnologist Will Czerniak, director, European operations at Hyde, added that the company has done business in the region since 1994 and now felt like the right time to expand.
Hyde has experienced an increase in projects in Europe, said Czerniak, and is optimistic that operations will grow in coming years. This is expected to lead to growth and expansion of the company’s services and staff.
Ireland was selected as the office location because of the talent and manufacturing capacity it provides for Hyde’s clients.
Savings in the downturn
Czerniak added that there has been “a dearth of large projects” during the economic downturn but smaller, more niche work has ensured “Hyde is busier than ever” and was well ahead of its targets in recent financials.
Forder explained that the economic situation facing biopharm companies means they increasingly “require greater efficiencies and significant reduction in the cost of goods”.
Hyde believes its services can help achieve these savings. The company’s offering spans process design and engineering, planning and project management, clean-in-place (CIP) and sterilisation-in-place (SIP), compliance engineering and training programmes.
Czerniak added that Hyde has experienced an upturn in projects and spending, giving the company reason to be optimistic that business is growing again.